COVID-19 vaccines
Find out how we approve and regulate COVID-19 vaccines in Australia.
We rigorously assess any COVID-19 vaccine for safety, quality and effectiveness before it can be supplied in Australia.
This page will be regularly updated to keep consumers, health professionals and sponsors informed of the latest regulatory developments.
For news and information on the COVID-19 vaccine roll-out strategy visit Department of Health and Aged Care: COVID-19 vaccines.
COVID-19 vaccine regulation
Report a side effect
If you think you have experienced a side effect from the COVID-19 vaccine you can report it via:
- Telephone: 1300 633 424 (9am-5pm AET, Monday to Friday) or visit www.1300medicine.com.au
- Online form: TGA adverse event reporting
Contact us
If you have an enquiry about the COVID-19 vaccine regulatory process, use the following contact details:
- Email: info@tga.gov.au(link sends e-mail)
- Telephone: 1800 020 653 (free call within Australia)
If you have a general enquiry about COVID-19 or the vaccine roll-out, contact the National Coronavirus Helpline on:
- Telephone: 1800 020 080 (available 24 hours a day, seven days a week)
Latest articles
-
Product Information safety updates - October 2024
Information for health professionals about medicines with safety related updates to their Product Information. -
Addressing misinformation about excessive DNA in the mRNA vaccines
We are aware of misinformation that claims the COVID-19 mRNA vaccines are contaminated with excessive levels of DNA. This is not the case. -
Product Information safety updates - September 2024
Information for health professionals about medicines with safety related updates to their product information.
Latest publications
-
Summary report of residual DNA and endotoxin on CoVID-19 mRNA vaccines conducted by TGA Laboratories
The TGA has conducted a comprehensive evaluation of the residual DNA and endotoxin levels in the two mRNA vaccines supplied in Australia - Comirnaty (Pfizer) and Spikevax (Moderna). -
Advisory Committee on Vaccines meeting statement for meeting 45, held on 4 October 2023.
-
Advisory Committee on Vaccines meeting statement for meeting 46, held on 29 November 2023.